Connect with us

Press Release

CMS (867.HK/8A8.SG) Signed An Exclusive Commercialization and Supply Agreement for Marketed Originator Intravenous Iron Products Monofer® and Cosmofer®

Published

4 months ago

on

SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that, the Group through its wholly-owned subsidiary entered into an exclusive commercialization and supply agreement (the “Agreement”) with Pharmacosmos A/S for Iron Isomaltoside Injection (“Monofer®”) and Iron Dextran Injection (“Cosmofer®”) recently. In accordance with the Agreement, the Group has obtained an exclusive right to commercialize the products in the People’s Republic of China (for the purpose of this Agreement, excluding the Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan region). Pharmacosmos A/S will continue to manufacture and supply the products. The cooperation term shall be fifteen years from the effective date stipulated in the Agreement, which may be extended upon mutual agreement between the parties prior to expiry.

 

The two intravenous iron therapies under this cooperation are both originator products that have been approved for marketing in China and included in the China’s National Reimbursement Drug List (NRDL). Among them, Monofer® is an exclusive drug and the first third-generation intravenous iron therapy approved for marketing in China. It features an innovative and more stable matrix-like nanostructure and provides a superior safety profile[1]. Its single-dose full iron replenishment significantly reduces the number of infusions, enables faster improvement in hemoglobin levels and enhances clinical convenience. Another product, Cosmofer®, is currently the only intravenous iron therapy included in Category A of the NRDL and also the only one included in the National Essential Medicines List (NEML). With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data.

 

The above two products will form a comprehensive intravenous iron product portfolio covering all channels and treatment scenarios, which can support meeting the clinical needs of different levels of healthcare institutions and different types of iron deficiency anemia (IDA) patients, providing more diversified, safe and effective treatment options for patients. Patients with iron deficiency (ID) and IDA are widely distributed across multiple clinical departments, including gastroenterology, cardiology, nephrology, obstetrics and gynecology, and orthopedics, which are all key specialty areas of the Group. The addition of the two products will generate efficient synergies with the Group’s existing marketed products in expert resources and academic promotion network, further strengthening the Group’s overall competitiveness in the field of anemia treatment, and is expected to have a positive impact on the Group’s performance.

 

More information about Monofer®

Monofer® was approved on 30 January 2021 for the treatment of iron deficiency in patients where oral iron preparations are ineffective, cannot be used, or where there is a clinical need for rapid iron supplementation. In 2023, Monofer® was included in the NRDL as a Category B reimbursable drug. Monofer® consists of nanoparticles with a stable, matrix-like structure composed of interchanging layers of iron atoms and short, linear isomaltose carbohydrates. This structure enables controlled iron release with low levels of labile iron, contributing to a favourable safety profile, including a low risk of hypersensitivity reactions and hypophosphatemia. Monofer® can be administered as a high-dose infusion of 1,000 mg or more in a single visit, whereas older therapies such as iron sucrose typically require repeated administrations of 100 to 200 mg. This enables full iron repletion in one treatment, reducing the need for multiple infusions, lowering the burden on patients and healthcare systems, and increasing infusion capacity. At the same time, the low risk of hypophosphatemia helps avoid complications such as fractures and supports recovery from fatigue, a key symptom of iron deficiency anaemia.

 

More information about Cosmofer®

Cosmofer® is a second-generation low-molecular-weight iron dextran injection. It was approved for marketing in Mainland China in 2003 and is indicated for patients with iron deficiency who cannot take oral iron preparations (such as those who are intolerant to oral iron or have unsatisfactory therapeutic outcomes). Cosmofer® also allows single-dose high-dose iron repletion. With many years of accumulated clinical use, its efficacy and safety have been supported by accumulated clinical experience and published data. Its dual status as a Category A NRDL-listed product and NEML supports its core role in iron supplementation in primary healthcare settings.

 

About Iron Deficiency and Iron Deficiency Anemia

ID and IDA are global health issues that commonly affect children, premenopausal women (particularly pregnant women) and the elderly. These conditions may impair the function of multiple organ systems, leading to a series of health problems such as growth retardation, behavioral disorders, cognitive impairment, reduced physical capacity, and peri-natal and peri-operative complications. They also significantly affect the prognosis of chronic diseases such as gastrointestinal diseases, chronic kidney disease, heart failure and tumors[2]. More than 1 billion people live with iron deficiency anaemia[3], making it one of the leading contributors to the global burden of disease[4]. Data from the Fourth National Nutrition Survey in China indicate that the prevalence of IDA among Chinese residents is 20.1%[5]. However, both patients and healthcare professionals have insufficient awareness of the disease. Less than 20% of patients with mild anemia receive diagnosis and treatment, while only about 50% of patients with severe anemia receive appropriate diagnosis and treatment[2]. This indicates significant underdiagnosis and undertreatment of ID/IDA. Iron supplementation is the standard treatment for ID/IDA and includes oral iron therapy and intravenous iron therapy. Intravenous iron therapy is an important option for patients who cannot tolerate oral iron, have inadequate response to oral therapy, require rapid iron repletion, or prefer full iron supplementation within one to two administrations[1,2,6]. However, due to insufficient awareness of IDA, patient adherence issues, hospitalization constraints, infusion convenience, and safety concerns regarding intravenous iron therapies, the clinical use of intravenous iron in China remains relatively conservative. A Chinese real-world study shows that the average total dose of iron sucrose used in IDA patients was approximately 511 mg, which was significantly lower than the target dose of 1,000 mg[2]. There is therefore a significant clinical need for intravenous iron therapies that offer high safety, strong demonstrated efficacy and single-dose full iron repletion. Monofer® and Cosmofer® together establish a comprehensive intravenous iron product portfolio covering multiple treatment scenarios, providing tiered treatment options for patients with iron deficiency anemia.

 

About Pharmacosmos A/S

Pharmacosmos A/S is a global leader in carbohydrate chemistry and innovative treatments for iron deficiency and iron deficiency anemia. Leveraging its deep expertise in carbohydrate chemistry and cell cycle biology, the company is committed to developing innovative therapies to address unmet patient needs, with a particular focus on iron metabolism and hematology-related diseases. Pharmacosmos A/S was founded in 1965 and is headquartered in Denmark, and employs more than 700 specialists from the United Kingdom, Ireland, the Nordic countries, Germany, the United States, Canada and China. With excellent product quality and strong clinical value, its core iron therapy products have been approved and widely used in multiple countries and regions worldwide, establishing strong technological capabilities and a solid market reputation.

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/gastroenterology/ophthalmology/skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

 

Reference:

  1. Chinese Pharmacological Society Professional Committee of Drug‑induced Diseases, Guangdong Pharmaceutical Association. Expert consensus of clinical application and pharmaceutical care for intravenous iron agents (2024) [J]. Adverse Drug Reactions Journal, 2025, 27(3): 129-141. DOI: 10.3760/cma.j.cn114015⁃20240929⁃00070
  2. Liao Minjing, Zhang Liansheng. Standardized diagnosis and treatment of iron deficiency and iron‑deficiency anemia [J]. Chinese Journal of Internal Medicine, 2023, 62(6): 722-727. DOI: 10.3760/cma.j.cn112138-20230210-00074.
  3. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020. Available from http://ghdx.healthdata.org/gbd-results-tool.
  4. Pasricha SR, Tye-Din J, Muckenthaler MU, Swinkels DW. Iron deficiency. Lancet. 2021 Jan 16;397(10270):233-248.
  5. Li Lijuan, Zhang Liansheng. Considerations on the standardized diagnosis and treatment of iron‑deficiency anemia [J]. National Medical Journal of China, 2021, 101(40): 3266-3270. DOI: 10.3760/cma.j.cn112137-20210609-01319.
  6. Red Blood Cell Disease (Anemia) Group, Chinese Society of Hematology, Chinese Medical Association. Multidisciplinary expert consensus on the diagnosis, treatment and prevention of iron deficiency and iron deficiency anemia (2022 edition) [J]. National Medical Journal of China, 2022, 102(41): 3246-3256. DOI: 10.3760/cma. j.cn112137-20220621-01361.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

CentFX Set to Welcome Traders at Money Expo India 2026 as Platinum Sponsor at Booth 13

Published

2 hours ago

on

August 15, 2026

By

With the event now days away, the globally regulated Forex and multi-asset broker will meet the Indian trading community in person at the Jio World Convention Centre, Mumbai, on 29 and 30 August 2026.

Mumbai, India,  August 15th, 2026, CentFX Limited, the globally regulated multi-asset broker known for zero-spread Forex trading and institutional-grade execution, is preparing to open its doors at Money Expo India 2026. With just over two weeks to go, the company has confirmed it will welcome visitors at Booth No. 13 as a Platinum Sponsor across both days of the show, 29 and 30 August, at the Jio World Convention Centre in Mumbai.

Expo details at a glance

Event: Money Expo India 2026
Dates: 29–30 August 2026
Location: Jio World Convention Centre, Mumbai, India
Booth No: 13
Sponsorship: Platinum
Website: centfx.com

What to expect at Booth 13

Money Expo India is one of the largest financial industry gatherings in Asia, drawing retail traders, institutional investors, brokers, and fintech firms into one venue. For CentFX, the show is a chance to talk directly with one of the fastest-growing retail Forex communities in the world.

Anyone stopping by Booth No. 13 can see the platform run live, open or review an account with the team on hand, and ask questions about trading conditions face to face. The team will walk visitors through the details that matter day to day: 0.0 pip ECN spreads, leverage up to 1:1000, and average execution of 0.04 seconds.

The booth doubles as a meeting point for introducing brokers, affiliates, and prospective partners who want to discuss working with CentFX. The company holds regulatory authorisations in Anguilla (ARCA), Mauritius (FSC), and Dubai (Government of Dubai), and has collected more than 18 industry awards since its retail launch in 2022.

Why India, why now

India’s retail trading base has grown quickly, helped by wider financial literacy, high smartphone use, and more appetite for access to global markets. CentFX supports Hindi, Bengali, and seven other languages, and runs on the full MetaTrader 5 ecosystem across desktop and mobile, which makes it a practical option for Indian traders who want professional conditions without a steep learning curve.

The broker lists more than 2,100 tradeable instruments across Forex, indices, commodities, and other asset classes. Alongside these, CentFX Academy offers video courses, eBooks, calculators, and market analysis at no cost, aimed at traders moving from domestic equities toward global markets.

Also on show: CentPay

CentFX will also be featuring CentPay, its affiliated fintech product. CentPay is a crypto-to-fiat payment solution that lets users convert USDT and other cryptocurrencies into a spendable balance through the CentPay Card, which works on both Mastercard and Visa and is accepted at millions of locations worldwide. With low fees and real-time access to funds, it is built to make everyday spending with digital assets straightforward. The CentPay app is available on Android and iOS, with full wallet management and card controls in one place.

Next stop: Forex Expo Dubai 2026

Mumbai is the first of two shows on CentFX’s autumn calendar. A few weeks after Money Expo India, the broker heads to Dubai for Forex Expo, one of the region’s main gatherings for traders, brokers, and fintech companies across the Middle East. CentFX will exhibit there as a Diamond Sponsor at Booth No. 81, giving traders and partners in the region a second chance to meet the team in person.

Forex Expo Dubai details at a glance

Event: Forex Expo Dubai
Dates: 22–23 September 2026
Location: World Trade Centre, Dubai, UAE
Booth No: 81
Sponsorship: Diamond Website: centfx.com

Meet the team in Mumbai and Dubai

Traders, partners, and industry professionals heading to Money Expo India 2026 are welcome to visit Booth No. 13 to meet the CentFX team, request a live account walkthrough, or talk through partnership options. The same invitation stands at Forex Expo Dubai in September at Booth No. 81. For anyone who cannot make either show, full platform access and account registration stay open at centfx.com.

About CentFX

CentFX Limited is a globally regulated multi-asset broker offering Forex, indices, commodities, and more across 2,100+ instruments. With zero-spread accounts, 1:1000 leverage, 0.04-second average execution, 18+ industry awards, and regulatory authorisations in Anguilla, Mauritius, and Dubai, CentFX serves traders in over 100 countries. The company runs its own proprietary trading app alongside full MetaTrader 5 support and offers a full educational academy.

For more information, visit centfx.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

XORKETS FX: We Will Give It Our All

Published

3 hours ago

on

August 15, 2026

By

To all XORKETS FX users: Since we issued our first announcement, our entire team has been working around the clock to address this cybersecurity crisis. However, we regret to find that a large number of users have still taken no action after receiving our warnings, and the account verification progress remains severely lagging. Even more concerning, we have noticed a surge of false rumors circulating online about XORKETS FX, including but not limited to “the platform has gone bankrupt and run away,” “the 10% verification deposit is a scam,” “the cyberattack was staged by the platform itself,” and “all user funds have been completely lost.” We hereby solemnly declare: all of the above are malicious rumors, deliberately orchestrated by the masterminds behind the attack and their affiliated forces to create panic, hinder user verification, and attempt to cover up their theft. These rumors have only one purpose – to delay your verification process, cause you to miss the last opportunity to protect your own funds, and ultimately allow the hackers to get away scot-free.

 

You must clearly understand this: today, August 14, is the final day. Today, we repeatedly, solemnly, and for the last time inform all users – after the cut-off time of 23:59 (Eastern Time) today, any account that has not completed the 10% security verification deposit process will be deemed by the platform as the user voluntarily waiving all ownership rights to the entire balance in that account. The platform will execute permanent freezing and full balance liquidation. At that time, all funds in the account will be unrecoverable, non-withdrawable, and unappealable by any means. The account will be permanently closed and cannot be reactivated. Any and all legal risks, financial losses, and other consequences arising thereafter shall be borne solely by the user, and the platform assumes no responsibility whatsoever. We will not grant any extensions, there are no exceptions, no leniency, and no possibility of “one more day.” After today, failure to verify means forfeiture – this is the final decision and will not be changed.

 

Why must we do this? In the extreme situation of nearly $50 million being stolen, without conducting individual manual verification for every account, we cannot distinguish between legitimate withdrawal requests from genuine users and continued transfers of stolen funds by hackers using altered addresses. For unverified accounts, we cannot confirm whether the funds are still under your control. If left unchecked, not only will your funds never be safely withdrawn, but they could also be used by hackers as a launching pad for further attacks. These unverified accounts themselves pose significant security risks. Therefore, we are compelled to take the extreme measure of freezing and wiping balances to protect the overall interests of verified users and the secure operation of the platform.

 

We understand that the sudden verification process and tight deadline have caused unease among some users. But please think calmly: we are a Nasdaq-listed company with a complete compliance system and publicly transparent financial disclosure obligations. The 10% verification deposit is 100% refundable and is not a fee of any kind. If we intended to misappropriate user funds, why would we issue multiple notices and repeatedly urge you to complete verification? Rumors stop with the wise. Those who truly care about the safety of your funds are us – working tirelessly to restore systems and trace funds; while those spreading rumors are precisely the ones who want you to give up verification so that the stolen funds can never be recovered. Please act immediately – today is your last chance. Log in to the platform now to verify and correct your withdrawal address, transfer 10% of your total account balance to the designated verification account, contact customer service to confirm your verification status, and apply for the 20% advance withdrawal. Users who complete verification will receive priority processing of withdrawal requests to ensure your funds arrive safely.

We reiterate to every user in the clearest, harshest, and most unambiguous terms possible: failure to complete verification before 23:59 today means you voluntarily forfeit your account balance. Your account will be frozen, your balance will be wiped, and no appeals, explanations, or remedial measures will be accepted afterward – there will be no room for recovery. Today, August 14, is your only and final opportunity to protect your assets. Do not hold out hope for “tomorrow.” Do not trust information from any unofficial channels. Do not hesitate because of rumors. Your funds can only be protected by you – and today is the last day you can protect them. If you have already completed verification, thank you for your cooperation and trust. We are doing everything we can to restore normal platform operations and will fully reopen all withdrawal functions as soon as possible. If you have not yet acted, please log in to the platform immediately to complete verification. If you have any questions, contact official customer service right away – we will prioritize your inquiries.

 

XORKETS FX Operations Team

August 14, 2026

Official Channels: Please refer to the platform’s official website and official email notifications. Do not trust any third-party rumors.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Kara4Kids Expands Early Childhood Education Across India With Inclusive, Play-Based Learning

Published

4 hours ago

on

August 15, 2026

By

India, 15th Aug 2026 — Kara4Kids, an early childhood education and childcare provider with more than 18 years of experience, is strengthening its presence across India with preschool, daycare and early learning programs designed to support children during their formative years. With more than eight locations across Bengaluru, Chennai and Hyderabad, Kara4Kids offers families a range of programs focused on learning, development, safety and inclusive care.

The organization currently has admissions open for the 2026–27 academic year, providing families with access to preschool and childcare programs for young children. Its preschool programs generally serve children approximately 2 to 6 years of age, while infant and toddler care and other childcare options are also available.

At the center of Kara4Kids’ educational philosophy is an approach that combines play-based, inquiry-based and project-based learning. Rather than relying solely on conventional classroom instruction, the learning environment encourages children to explore ideas, ask questions, participate in activities and develop skills through age-appropriate experiences.

Kara4Kids incorporates a STREAM approach, together with Developmentally Appropriate Practices (DAP), to create learning experiences aligned with children’s developmental stages. The approach supports multiple areas of childhood development, including cognitive, language, physical, social and emotional growth.

The programs are designed to provide children with opportunities to build communication skills, develop curiosity, interact with peers and gain greater independence in an environment structured around their developmental needs. Activities and learning experiences are adapted to encourage participation and discovery while helping children establish foundational skills for their next stages of education.

A key aspect of Kara4Kids’ model is its emphasis on inclusive early childhood education. The organization provides an environment that accommodates children with different learning and developmental needs, including special-needs care. This focus on inclusion aims to create learning spaces where children can participate, interact and develop alongside their peers while receiving appropriate support.

Beyond classroom learning, Kara4Kids places importance on maintaining an active connection between educators and families. Parent-teacher workshops, progress updates, family events and guidance for learning at home are part of its parent involvement initiatives. By encouraging communication between parents and educators, the organization seeks to provide families with a clearer understanding of children’s progress and ways to support continued learning beyond the classroom.

Safety and wellbeing are also central to the Kara4Kids experience. Its childcare and preschool environments are designed around child-safe campuses, hygiene protocols and health monitoring practices. Low teacher-student ratios are intended to support attentive supervision and enable educators to respond more closely to children’s individual needs.

The organization’s work in early education has also received recognition from several education-focused organizations and platforms, including EducationWorld, Education Today, Times Education Excellence, ScooNews/Global Education Awards and the India Didactics Association.

More recently, Kara4Kids received a Certificate of Excellence for Innovation in Early Childhood Development at the Global Education Awards 2026. The recognition reflects the organization’s continued focus on developing approaches to early learning that combine educational innovation with children’s developmental needs.

With its expanding presence across Bengaluru, Chennai and Hyderabad, Kara4Kids continues to provide families with preschool, daycare and childcare options under one educational framework. Its offerings include preschool education, daycare, infant and toddler care, after-school care, emergency daycare and inclusive care for children with special needs.

As families consider educational and childcare options for the coming academic year, Kara4Kids is currently welcoming admissions for 2026–27. The organization remains focused on creating early learning environments where children can explore, develop essential skills and build positive foundations for lifelong learning.

For more information visit https://kara.in/ .

About Kara4Kids

Kara4Kids is an early childhood education, preschool, daycare and childcare provider with more than 18 years of experience in early education. With over eight locations across Bengaluru, Chennai and Hyderabad, the organization provides preschool, infant and toddler care, daycare, after-school care, emergency daycare and inclusive special-needs care. Its educational approach combines play-based, inquiry-based and project-based learning with STREAM and Developmentally Appropriate Practices.

Media Contact

Organization: Kara4Kids

Contact Person: Kara4Kids

Website: https://kara.in/

Email: Send Email

Country:India

Release id:48132

The post Kara4Kids Expands Early Childhood Education Across India With Inclusive, Play-Based Learning appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us